- Home
- GOVX vs VYNE Comparison
GOVX vs VYNE Comparison
Compare GOVX & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- VYNE
- Stock Information
- Founded
- GOVX 2001
- VYNE 2003
- Country
- GOVX United States
- VYNE United States
- Employees
- GOVX N/A
- VYNE N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- GOVX Health Care
- VYNE Health Care
- Exchange
- GOVX Nasdaq
- VYNE Nasdaq
- Market Cap
- GOVX 7.6M
- VYNE 7.9M
- IPO Year
- GOVX N/A
- VYNE 2018
- Fundamental
- Price
- GOVX $0.68
- VYNE $0.30
- Analyst Decision
- GOVX Strong Buy
- VYNE Buy
- Analyst Count
- GOVX 3
- VYNE 2
- Target Price
- GOVX $10.67
- VYNE $8.00
- AVG Volume (30 Days)
- GOVX 690.2K
- VYNE 1.8M
- Earning Date
- GOVX 11-11-2025
- VYNE 11-06-2025
- Dividend Yield
- GOVX N/A
- VYNE N/A
- EPS Growth
- GOVX N/A
- VYNE N/A
- EPS
- GOVX N/A
- VYNE N/A
- Revenue
- GOVX $6,143,044.00
- VYNE $476,000.00
- Revenue This Year
- GOVX N/A
- VYNE N/A
- Revenue Next Year
- GOVX N/A
- VYNE N/A
- P/E Ratio
- GOVX N/A
- VYNE N/A
- Revenue Growth
- GOVX 1943.07
- VYNE N/A
- 52 Week Low
- GOVX $0.43
- VYNE $0.28
- 52 Week High
- GOVX $3.88
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- GOVX 41.08
- VYNE 31.93
- Support Level
- GOVX $0.65
- VYNE $0.28
- Resistance Level
- GOVX $0.73
- VYNE $0.33
- Average True Range (ATR)
- GOVX 0.04
- VYNE 0.02
- MACD
- GOVX -0.00
- VYNE 0.03
- Stochastic Oscillator
- GOVX 21.28
- VYNE 36.38
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.